Dare Bioscience DARE
NASDAQ DARE
$0.66 -0.03 (-4.91%)
As of: Nov 12, 2026 · 11:53 AM EST

Dare Bioscience (DARE) Cost of Revenue (2026)

Updated

Dare Bioscience's Cost of Revenue was $319,889 in Q2 2026.

Analysis

Dare Bioscience (DARE) Cost of Revenue (2026) Analysis & Trends

For FY2025, Cost of Revenue at Dare Bioscience came in at $295,799.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 3.93 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.10 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 4.29 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.89 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 2.95 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 2.79 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.57 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.03 Bn
10 Dare Bioscience 10.47 Mn -68.48 Mn -132,343.00 319,889.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 319,889.00
Mar 31, 2026 242,325.00
API Access

Dare Bioscience Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=DARE&period=max&api_key=YOUR_API_KEY